Results 21 to 30 of about 2,329 (147)

Uso de Ozanimod para la esclerosis múltiple [PDF]

, 2023
Objective: The overall objective of the research was to describe the use of Ozanimod for multiple sclerosis.Method: It was developed from a quantitative approach and a descriptive literature review, where the therapeutic potential of Ozanimod for MS was ...
Clavijo-Rosales , Claudia Gabriela, Claudia Gabriela Clavijo-Rosales, Cajamarca-Naranjo, Galo Vinicio, Galo Vinicio Cajamarca-Naranjo   +3 more
core   +3 more sources

Ozanimod induction and maintenance treatment for ulcerative colitis [PDF]

, 2016
BACKGROUND: Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral lymphocyte sequestration, potentially decreasing the number of activated lymphocytes circulating to the gastrointestinal ...
Ghosh, Subrata, Hanauer, Stephen B., Frohna, Paul A., Vermeire, Severine, Gujrathi, Sheila, Feagan, Brian G., Olson, Allan, D'Haens, Geert, Sandborn, William J., Wolf, Douglas C., Smith, Heather, Aranda, Richard, Cravets, Matthew   +12 more
core   +6 more sources

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease. [PDF]

J Gastroenterol Hepatol
ABSTRACT Ulcerative colitis (UC) and Crohn's disease (CD) are increasingly prevalent in the Asia Pacific region, necessitating updated, region‐specific guidance on advanced therapies. Targeted small molecule agents, such as filgotinib, tofacitinib, upadacitinib, etrasimod, and ozanimod; and the IL‐23 p19 inhibitors (guselkumab, mirikizumab ...
Ooi CJ, Ling KL, Limsrivilai J, Wei SC, Mak JWY, Kobayashi T, Dang LM, Leong RW, Lin H, Weng MT, Ong WC, Ahuja V, Aniwan S, Hokari R, Lee WJJ, Leow AH, Leung WK, Lim WC, Makharia G, Matsuoka K, Mustaffa N, Ng SC, Philip M, Pisespongsa P, Ali RAR, Ran ZH, Simadibrata M, Sollano J, Tan M, Viet HD, Wan Ibrahim NR, Wu KC, Ye BD, Hilmi I, Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease Committee and Asian Education Network in IBD (AEN‐IBD).   +34 more
europepmc   +2 more sources

Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program [PDF]

, 2021
Esdeveniments adversos; Esclerosi múltiple; OzanimodEventos adversos; Esclerosis múltiple; OzanimodAdverse events; Multiple sclerosis; OzanimodBackground Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple ...
Bar-Or, Amit, Arnold, Douglas L, Steinman, Lawrence, Montalban Gairín, Xavier, Selmaj, Krzysztof W., Cohen, Jeffrey A, Comi, Giancarlo   +6 more
core   +3 more sources

Tacrolimus Bridging and Combination Therapy Following Infliximab and JAK Inhibitor Failure in Ulcerative Colitis: A Case Series. [PDF]

JGH Open
ABSTRACT Background Calcineurin inhibitors such as tacrolimus are established rescue therapies for steroid‐refractory ulcerative colitis (UC). However, their efficacy and safety as bridging or combination therapy following failure of both anti‐tumor necrosis factor (anti‐TNF) and Janus kinase (JAK) inhibitor therapy remain uncertain.
Vootukuru N, Hilley P, Wong D, Srinivasan A, De Cruz P, Choy M.   +5 more
europepmc   +2 more sources

Selective Sphingosine 1-Phosphate Receptor 1 Modulation Augments Thrombolysis of Low-Dose Tissue Plasminogen Activator Following Cerebrovascular Thrombosis

Frontiers in Immunology, 2022
BackgroundResults from our recent study demonstrate that sphingosine-1-phosphate receptor 1 (S1PR1) modulation improves microvascular hemodynamics after cerebrovascular thrombosis.
Han-Dong Li, Ran Li, Ying Kong, Wenyan Zhang, Caiyun Qi, Dan Wang, Hongying Hao, Qiang Liu   +7 more
doaj   +1 more source

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany

Frontiers in Neurology, 2022
Background:Ozanimod, a sphingosine 1-phosphate receptor 1 and 5 modulator, was approved as a disease-modifying therapy for active relapsing-remitting multiple sclerosis (RRMS) in 2020 and for active ulcerative colitis in 2021.
Tjalf Ziemssen, Stephan Richter, Mathias Mäurer, Mathias Buttmann, Boris Kreusel, Anne-Maria Poehler, Maren Lampl, Ralf A. Linker   +7 more
doaj   +1 more source

Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frontiers in Pharmacology, 2020
Background: Ozanimod has been approved for use in the treatment of relapsing forms of multiple sclerosis by the United States FDA. As a novel, orally available sphingosine 1-phosphate receptor modulator, ozanimod selectively binds to S1P1 and S1P5 ...
Yue Sun, Yue Sun, Yanbo Yang, Zilan Wang, Fan Jiang, Zhouqing Chen, Zhong Wang   +6 more
doaj   +1 more source

Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5

Frontiers in Pharmacology, 2022
Ozanimod, a sphingosine 1-phosphate (S1P) receptor modulator, binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5), and is approved in multiple countries for treating adults with relapsing forms of multiple sclerosis (MS ...
Julie V. Selkirk, Andrea Bortolato, Yingzhuo Grace Yan, Nathan Ching, Richard Hargreaves   +4 more
doaj   +1 more source

Bioavailable central nervous system disease-modifying therapies for multiple sclerosis

Frontiers in Immunology, 2023
Disease-modifying therapies for relapsing multiple sclerosis reduce relapse rates by suppressing peripheral immune cells but have limited efficacy in progressive forms of the disease where cells in the central nervous system play a critical role.
Hans-Peter Hartung, Hans-Peter Hartung, Hans-Peter Hartung, Hans-Peter Hartung, Bruce A.C. Cree, Michael Barnett, Sven G. Meuth, Amit Bar-Or, Lawrence Steinman   +8 more
doaj   +1 more source